Martin Shkreli ordered to pay $64m and banned for life from pharmaceutical industry

Martin Shkreli ordered to pay $64m and banned for life from pharmaceutical industry
Shkreli hiked the price of a life saving drug from $13 per tablet to $750 per tablet

The so-calledPharma BroMartin Shkreli has been bannedfor life from participating in the pharmaceutical industry in any capacityby a federal judge. He will also be forced to pay a $64.6m disgorgement to states that brought an antitrust lawsuit against him, Volgens Law & Misdaad.

Shkreli is no stranger to controversy, but his latest trouble started in January 2020, after New York Attorney General Letitia James filed a lawsuit against him accusing him of using his monopoly control of the drug Daraprim to gouge its price.

The drug is used to treat toxoplasmosis, which can be fatal, especially in people with compromised immune systems.

When Shkreli’s company, Turing Pharmaceuticals, bought the drug in 2015, the price jumped from $13.50 a tablet to $750 a tablet.

Op daardie stadium, the Infectious Diseases Society of America and the HIV Medicine Association issued a joint letter to the company – which has rebranded as Vyera – saying the price hike wasunjustifiable for the medically vulnerable patient populationand claimed it wasunsustainable for the health care system.

Eventually the Federal Trade Commission joined Ms Jameslawsuit against Shkreli.

Ms James celebrated the ruling in a Twitter post on Friday.

Martin Shkreli is a ‘Pharma Brono more,” sy het geskryf. “The powerful don’t get to make their own rules, despite Shkreli thinking cash rules everything around him.

The judge ruled that Shkreli’s scheme washeartless and coercive.

“Daraprim must be administered within hours to those suffering from active toxoplasma encephalitis,” het die regter gesê.

The judge’s ruling focused on Shkreli’s strategy of cornering the market and hiking the price.

“From day one, Shkreli focused his new venture on acquiring sole-source drugs that were the gold standard treatment option for life-threatening diseases with a small patient population and inferior alternative treatments, with the intent to raise their prices, block generic competition, and reap extraordinary profits,” the judge stated in the ruling.

The judge also noted that Shkreli never showed remorse or regret for making it prohibitively expensive for patients to access the drugs they needed to survive.

“Verder, in the face of public opprobrium, Shkreli doubled down,” the judge wrote. “He refused to change course and proclaimed that he should have raised Daraprim’s price higher.”

Uiteindelik, the judge decided to ban Shkreli from participating in the pharmaceutical industry to ensure he cannot continue participating inanticompetitive conduct.

“Shkreli established two companies, Retrophin and Vyera, with the same anticompetitive business model: Acquiring sole-source drugs for rare diseases so that he could profit from a monopolist scheme on the backs of a dependent population of pharmaceutical distributors, healthcare providers, and the patients who needed the drugs,” the judge wrote in the ruling.

Even after going to prison on unrelated fraud charges, Shkreli kept the price of the drug high. He was accused of maintainingshadow controlof the company while in prison, with the judge noting that he threatened touse his authority as the largest shareholder to call an extraordinary general meeting that would install more pliant officers and directors,” all of which wereloyaliststo his leadership.

The judge wrote that Shkrelirecklessly disregarded the health of a particularly vulnerable population, those with compromised immune systems

His scheme burdened those patients, their loved ones, and their healthcare providers,” the ruling stated.

Shkreli attempted to secure a release from prison in 2020 by claiming he could help stop the coronavirus pandemic, despite having no formal medical training.

His lawyers at the time claimed that he had beenconducting significant researchinto finding a treatment for Covid-19 while serving out his prison sentence. His request was denied.

Laat 'n antwoord

U e-posadres sal nie gepubliseer word nie. Vereiste velde is gemerk *